ICU Medical, Inc. — Form 10-Q Summary
Reporting period: Three and nine months ended September 30, 2022. Filed November 7, 2022. ICU Medical develops, manufactures and sells infusion therapy and critical-care products. Results include Smiths Medical from January 7, 2022, following its acquisition on January 6, 2022; year-over-year comparisons are therefore not like-for-like.
Key financial results
Amounts below are in millions, except per-share data and percentages.
| Metric | Q3 2022 | Q3 2021 | Nine months 2022 | Nine months 2021 |
|---|---|---|---|---|
| Revenue | $597.9 | $336.1 | $1,702.0 | $975.8 |
| Gross profit / margin | $186.4 / 31.2% | $127.8 / 38.0% | $522.8 / 30.7% | $364.0 / 37.3% |
| Operating income (loss) | $(0.5) | $38.4 | $(42.7) | $99.4 |
| Net income (loss) | $(13.2) | $31.1 | $(58.8) | $83.2 |
| Diluted EPS | $(0.55) | $1.43 | $(2.47) | $3.83 |
| Operating cash flow | Not separately provided for quarter | $(60.4) | $184.9 |
- Revenue increased 77.9% in Q3 and 74.4% year to date, largely reflecting the acquired Smiths Medical business. Smiths Medical contributed estimated revenue of $261.4 million in Q3 and $699.1 million from acquisition through September 30.
- Gross margin declined as acquired Smiths Medical margins were lower, alongside purchase-accounting inventory amortization, quality-system and product-remediation spending, expedited freight, inflation, foreign-exchange effects and lower manufacturing absorption from supply disruptions.
- Operating expenses included $14.4 million of restructuring, strategic transaction and integration expense in Q3 and $61.8 million year to date. A fair-value gain on contingent earn-outs reduced operating expenses by $4.1 million in Q3 and $31.3 million year to date.
- Interest expense was $21.2 million in Q3 and $51.1 million year to date, principally reflecting acquisition-related borrowings and financing costs. The year-to-date tax benefit was $34.2 million.
Financial position and liquidity
- At September 30, 2022, cash and cash equivalents were $243.9 million and short-term investments were $2.9 million; combined cash and short-term investments were $246.8 million, down from $567.2 million at year-end 2021.
- Inventory was $625.3 million, compared with $290.2 million at year-end. Management attributed the increase to the acquisition and inventory safety-stock building. The filing reports a $151.8 million operating cash outflow from increased inventories.
- Long-term debt had a carrying value of $1.654 billion, including $24.4 million current; principal outstanding was approximately $1.680 billion. The $500 million revolving facility was undrawn. ICU Medical reported compliance with its financial covenants at quarter-end.
- Investing cash outflow was $1.885 billion for the nine months, including $1.844 billion for acquisitions, net of acquired cash. Financing cash inflow was $1.647 billion, primarily from new term loans. Capital expenditures were $68.7 million.
- Management stated that cash, expected operating cash flows and available credit were expected to fund requirements for the next 12 months, while cautioning that weaker demand, unplanned expenditures or adverse conditions could require alternative financing.
Material changes and management commentary
- The Smiths Medical acquisition added syringe and ambulatory infusion, vascular-access and vital-care products and materially expanded operations. It was funded with approximately $1.9 billion cash consideration, 2.5 million ICU Medical shares valued at $576.0 million, and acquisition-related debt. Purchase-price allocation remained preliminary.
- Legacy product-line trends were mixed. Q3 revenue declined for infusion consumables, infusion systems and critical care, while IV Solutions increased, primarily from higher Pfizer contract-manufacturing sales. Management cited foreign exchange as a factor in declines; Smiths Medical product lines faced supply-chain and fulfillment constraints and currency impacts.
- Management said COVID-19, the Russia-Ukraine conflict, supply disruptions, inflation—particularly freight, labor and raw materials—and a stronger U.S. dollar had pressured margins. The extent of future effects remained uncertain. The filing provides no specific financial guidance.
- Smiths Medical’s acquired FDA Warning Letter concerned device-reporting and quality-system issues at its Oakdale facility. The estimated field service corrective-action liability was $47.5 million at September 30, down from $55.1 million recorded at acquisition; actual costs could differ depending on work needed for regulatory clearance.
- The acquisition earn-out had an estimated fair value of $21.8 million at September 30, contingent on ICU Medical share-price targets. Changes in its fair value affect reported operating results. Foreign-currency translation also contributed to comprehensive loss.
- Management concluded disclosure controls were effective at a reasonable assurance level, but excluded Smiths Medical from the assessment of internal control over financial reporting as a newly acquired business. Smiths represented about 40% of consolidated assets and 44% and 41% of Q3 and year-to-date revenue, respectively.
Investor verification priorities
- Separate acquired Smiths Medical revenue and costs from legacy performance, and assess whether supply, fulfillment and integration issues are improving.
- Track gross-margin recovery, including the effects of inflation, foreign exchange, freight, purchase-accounting inventory charges and quality remediation.
- Monitor operating cash conversion and working-capital requirements, especially inventory levels, receivables and accrued liabilities.
- Review debt balances, floating-rate exposure, covenant headroom and refinancing or repayment obligations; the filing estimates a $16.8 million annual interest-cost sensitivity to a 1% SOFR change before considering hedges.
- Follow progress on the Smiths Medical FDA corrective action and validate the adequacy of its $47.5 million estimated liability, as well as the preliminary acquisition valuations and earn-out assumptions.